Cargando…

Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer

PURPOSE: Gallium-68 (Ga-68)-labeled tracers for imaging expression of the prostate-specific membrane antigen (PSMA) such as the [(68)Ga]Ga-PSMA-HBED-CC have already demonstrated high potential for the detection of recurrent prostate cancer. However, compared to Ga-68, a labeling with fluorine-18 (F-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dietlein, Markus, Kobe, Carsten, Kuhnert, Georg, Stockter, Simone, Fischer, Thomas, Schomäcker, Klaus, Schmidt, Matthias, Dietlein, Felix, Zlatopolskiy, Boris D., Krapf, Philipp, Richarz, Raphael, Neubauer, Stephan, Drzezga, Alexander, Neumaier, Bernd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493776/ https://www.ncbi.nlm.nih.gov/pubmed/26013479 http://dx.doi.org/10.1007/s11307-015-0866-0

Ejemplares similares

Uptake in non-affected bone tissue does not differ between [(18)F]-DCFPyL and [(68)Ga]-HBED-CC PSMA PET/CT
por: Hammes, Jochen, et al.
Publicado: (2018)

Threshold for defining PSMA-positivity prior to (177)Lu-PSMA therapy: a comparison of [(68)Ga]Ga-PSMA-11 and [(18)F]F-DCFPyL in metastatic prostate cancer
por: Heilinger, Jan, et al.
Publicado: (2023)

(68)Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients
por: Sathekge, Mike, et al.
Publicado: (2016)

High uptake of (68)Ga-PSMA and (18)F-DCFPyL in the peritumoral area of rat gliomas due to activated astrocytes
por: Oliveira, Dennis, et al.
Publicado: (2020)

Intra-individual comparison of (68)Ga-PSMA-11 and (18)F-DCFPyL normal-organ biodistribution
por: Ferreira, Gonçalo, et al.
Publicado: (2019)

Repeatability of (68)Ga-PSMA-HBED-CC PET/CT–Derived Total Molecular Tumor Volume
por: Seifert, Robert, et al.
Publicado: (2022)

[(18)F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer
por: Dietlein, Felix, et al.
Publicado: (2020)

Novel Preclinical and Radiopharmaceutical Aspects of [(68)Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
por: Eder, Matthias, et al.
Publicado: (2014)

Biodistribution and radiation dosimetry of [(18)F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer
por: Hohberg, Melanie, et al.
Publicado: (2019)

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2014)

(68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison
por: Zamboglou, Constantinos, et al.
Publicado: (2016)

Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

Characterization of SnO(2)-based (68)Ge/(68)Ga generators and (68)Ga-DOTATATE preparations: radionuclide purity, radiochemical yield and long-term constancy
por: Sudbrock, Ferdinand, et al.
Publicado: (2014)

Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with (68)Ga-PSMA-HBED-CC PET-positive prostate cancer lesions
por: Meißner, Sebastian, et al.
Publicado: (2017)

Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer
por: Jilg, Cordula A., et al.
Publicado: (2017)

(68)Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study
por: van Boxtel, Wim, et al.
Publicado: (2020)

Intra-patient comparison of physiologic (68)Ga-PSMA-11 and (18)F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay
por: Osman, Medhat M., et al.
Publicado: (2021)

Focal dose escalation for prostate cancer using (68)Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference
por: Zamboglou, Constantinos, et al.
Publicado: (2018)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

Can Early Dynamic Positron Emission Tomography/Computed Tomography Obviate the Need for Postdiuresis Image in (68)Ga-PSMA-HBED-CC Scan for Evaluation of Prostate Adenocarcinoma?
por: Perveen, Gazala, et al.
Publicado: (2018)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

In vitro and in vivo comparative study of a novel (68)Ga-labeled PSMA-targeted inhibitor and (68)Ga-PSMA-11
por: Chen, Huanyu, et al.
Publicado: (2021)

PSMA PET/CT with Glu-urea-Lys-(Ahx)-[(68)Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer
por: Giesel, Frederik L., et al.
Publicado: (2015)

68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective single-institutional study
por: Martinez, Juana, et al.
Publicado: (2021)

Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis
por: Pan, Ke-Hao, et al.
Publicado: (2021)

PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and (68)Ga‐PSMA‐11 PET Using Cyclotron‐Produced (68)Ga
por: Thompson, Scott M., et al.
Publicado: (2021)

Comparison of (68)Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology
por: Zamboglou, Constantinos, et al.
Publicado: (2017)

PSMA Expression in Multinodular Thyroid Neoplasm on Simultaneous Ga-68-PSMA PET/MRI
por: Jena, Amarnath, et al.
Publicado: (2017)

Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted (18)F-DCFPyL in peripheral ganglia
por: Werner, Rudolf A., et al.
Publicado: (2017)

(18)F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer
por: Mesci, Aruz, et al.
Publicado: (2023)

Musculoskeletal pitfalls in (68)Ga-PSMA PET/CT
por: Pontes, Írline Cordeiro de Macedo, et al.
Publicado: (2023)

Cyclotron-based production of (68)Ga, [(68)Ga]GaCl(3), and [(68)Ga]Ga-PSMA-11 from a liquid target
por: Rodnick, Melissa E., et al.
Publicado: (2020)

Incidental Detection of Asymptomatic Brain Metastases Due to Carcinoma Prostate in Ga-68 PSMA HBED-CC Positron Emission Tomography-Computed Tomography: Reiterating its Superiority in Assessing Disease Status
por: Nellaiappan, Harihara Sudhan, et al.
Publicado: (2022)

PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [(68)Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression
por: Rosar, Florian, et al.
Publicado: (2022)

[(68)Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [(177)Lu]Lu-PSMA therapy in relapsing high-grade glioma
por: Truckenmueller, Peter, et al.
Publicado: (2022)

(68)Ga-HBED-CC-WL-12 PET in Diagnosing and Differentiating Pancreatic Cancers in Murine Models
por: Xiang, Qiying, et al.
Publicado: (2023)

Higher Preoperative Maximum Standardised Uptake Values (SUV(max)) Are Associated with Higher Biochemical Recurrence Rates after Robot-Assisted Radical Prostatectomy for [(68)Ga]Ga-PSMA-11 and [(18)F]DCFPyL Positron Emission Tomography/Computed Tomography
por: de Bie, Katelijne C. C., et al.
Publicado: (2023)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

A Prospective Study on (18)F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
por: Rousseau, Etienne, et al.
Publicado: (2019)

Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents
por: Endepols, Heike, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cq66a2nacp2ifc13dfod5fgnut